1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010; 303: 235–4.
2. Murugan AT. Obesity and respiratory diseases. Chronic Respiratory Disease November 2008; 5 (4): 233–42.
3. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006; 6: 438–46.
4. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18: 313–25.
5. Trayhurn P, Wood I. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005; 33: 1078–81.
6. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347–55.
7. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 2008; 37: 753–68.
8. Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009; 117: 241–50.
9. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Prac Res Clin Endocrinol Metab 2005; 19: 547–66.
10. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537–56.
11. Morrison CD. Leptin resistance and the response to positive energy balance. Physiol Behav 2008; 94: 660–3.
12. Otero M, Lago R, Lago F et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005; 579: 295–301.
13. Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med 2010; 235 (12): 1412–24.
14. Lamas O, Marti A, Martinez JA. Obesity and immunocompetence. Eur J Clin Nutr 2002; 56 (Suppl. 3): S42–45.
15. Resta O, Foschino-Barbaro MP, Legari G et al. Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord 2001; 25: 669–75.
16. Murugan AT. Obesity and respiratory diseases. Chronic Respiratory Disease 2008; 5 (4): 233–42.
17. Guerra S, Sherrill DL, Bobadilla A et al. The Relation of Body Mass Index to Asthma, Chronic Bronchitis, and Emphysema Chest 2002; 122 (4): 1256–63.
http://thorax.bmj.com/content/63/7/649.full - aff-1
18. McClean KM, Kee F. http://thorax.bmj.com/content/ 63/7/ 649.full – aff-1 F., Young IS, Elborn JS. http://thorax.bmj.com/ content/63/7/649.full – aff-3 Obesity and the lung: 1 Epidemiology Thorax 2008; 63: 649–54.
19. Beuther DA et al. Am J Respir Crit Care Med 2007; 175 (7): 661–6.
20. Koenig SM. Pulmonary complications of obesity. Am J Med Sci 2001; 321: 249–79.
21. Beal M, Chesson A, Garcia T et al. A pilot study of quantitative aspiration in patients with symptoms of obstructive sleep apnea: comparison to a historic control group. Laryngoscope 2004; 114: 965–8.
22. Rubinstein I. Nasal infl ammation in patients with obstructive sleep apnea. Laryngoscope 1995; 105: 175–7.
23.Salerno FG, Carpagnano E, Guido P et al. Airway inflammation in patients aff ected by obstructive sleep apnea syndrome. Respir Med 2004; 98: 25–8.
24. Vaughan RW, Conahan TJ 3rd. Part I: cardiopulmonary consequences of morbid obesity. Life Sci 1980; 26: 2119–27.
25. Vaughan RW, Bauer S, Wise L. Volume and pH of gastric juice in obese patients. Anesthesiology 1975; 43: 686–9.
26. Marik P, Varon J. The obese patient in the ICU. Chest 1998; 113: 492–8.
27. Baik I, Curhan GC, Rimm EB et al. A prospective study of age and lifestyle factors in relation to community acquired pneumonia in US men and women. Arch Intern Med 2000; 160: 3082–8.
28. Jedrychowski W, Maugeri U, Flak E et al. Predisposition to acute respiratory infections among overweight preadolescent children: an epidemiologic study in Poland. Public Health 1998; 112: 189–95.
29. Mancuso Р. Obesity and respiratory infections: Does excess adiposity weigh down host defense? Pulm Pharmacol Ther 2012 May 24 [Epub ahead of print].
31. Geerlings SE et al. FEMS Immunol Med Microbiol 1999; 
26 (3–4): 259–65.
32. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 375: 248–51.
33. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621–5.
34. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119–33.
35. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000; 38: 415–26.
36. Stein GE, Schooley SL, Peloquin CA et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39: 427–32.
37. Lamas O, Marti A, Martinez JA. Obesity and immunocompetence. Eur J Clin Nutr 2002; 56 (Suppl. 3): S42–45.
38. Mathison CJ. Skin and wound care challenges in the hospitalized morbidly obese patient. J Wound Ostomy Continence Nurs 2003; 30: 78–83.
39. Bosma RJ, Krikken JA, Homan van der Heide JJ et al. Obesity and renal hemodynamics. Contrib Nephrol 2006; 151: 184–202.
40. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081–91.
41. Pearson TC, Guthrie DL, Simpson J et al. Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89: 748–56.
42. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999; 88: 1–7.
43. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике. Смоленск: Русич, 1998.
44. Bauernfeind A. In vitro activity of diritrimycin in comparison with other new and established macrolides. J Antimicrob Chemother 1993; 31 (Suppl.): 39–49.
45. Zarogoulidis P, Papanas N, Kioumis I et al. Macrolides:from in vitro anti–inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol Epub 2011; 22.
46. Cazzola M, Blasi F, Ewig S. Antibiotics and the Lung. European Respiratory Momograph 2004; 9: 28.
47. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125 (Suppl.): 41–51.
48. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo–controlled crossover trial. Lancet 2002; 360: 978–84.
49. Amsden GW. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions. J Antimicrob Chemother 2005; 55 (1): 10–21.
50. Panpanich R et al. Cochrane Database Syst Rev 2008; (1): CD00195.
51. Murray JJ et al. Otolaryngol Head Neck Surg 2005; 133 (2): 194–200.

Л.И.Дворецкий 

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ